ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2021. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,671,443 | -18.2% | 1,224,118 | +0.7% | 0.10% | -9.8% |
| Q2 2023 | $8,156,173 | -21.0% | 1,215,525 | +3.9% | 0.11% | -34.5% |
| Q1 2023 | $10,326,862 | -61.0% | 1,169,520 | +24.1% | 0.17% | +13.2% |
| Q4 2021 | $26,451,000 | -60.5% | 942,666 | -52.1% | 0.15% | -56.5% |
| Q3 2021 | $66,951,000 | -20.1% | 1,969,726 | -3.9% | 0.35% | -15.6% |
| Q2 2021 | $83,762,000 | -12.7% | 2,049,963 | -14.0% | 0.41% | -20.5% |
| Q1 2021 | $95,988,000 | -31.6% | 2,384,205 | +0.4% | 0.52% | -25.8% |
| Q4 2020 | $140,422,000 | +20.5% | 2,374,798 | -0.9% | 0.70% | -2.9% |
| Q3 2020 | $116,580,000 | -1.9% | 2,397,279 | -2.4% | 0.72% | -22.7% |
| Q2 2020 | $118,786,000 | +87.6% | 2,455,269 | +7.7% | 0.93% | +22.4% |
| Q1 2020 | $63,318,000 | +169.5% | 2,279,250 | +190.3% | 0.76% | +211.1% |
| Q4 2019 | $23,493,000 | -4.1% | 785,198 | -0.9% | 0.24% | -13.2% |
| Q3 2019 | $24,492,000 | -14.3% | 792,621 | +33.9% | 0.28% | -2.4% |
| Q2 2019 | $28,581,000 | – | 591,749 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 1,014,860 | $14,086,000 | 3.47% |
| Triatomic Management LP | 297,048 | $4,123,000 | 3.35% |
| Diametric Capital, LP | 265,000 | $3,678,000 | 2.03% |
| Matrix Capital Management Company, LP | 11,572,590 | $160,628,000 | 1.93% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $416,313,000 | 1.68% |
| TIGER MANAGEMENT L.L.C. | 589,311 | $8,180,000 | 1.35% |
| Aristotle Atlantic Partners, LLC | 759,412 | $10,541,000 | 0.65% |
| Casdin Capital, LLC | 1,000,000 | $13,880,000 | 0.62% |
| Pier Capital, LLC | 339,541 | $4,713,000 | 0.60% |
| Leeward Financial Partners, LLC | 68,504 | $951,000 | 0.59% |